Gilead says additional data on remdesivir shows improved clinical recovery
Gilead said it analyzed data from 312 patients treated in a late-stage study
Health and Human Services Secretary Alex Azar on how hospitals will supply coronavirus drug Remdesivir 'out of pocket.'
Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.
The company said the finding requires confirmation in prospective clinical trials.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC. | 88.46 | +0.06 | +0.07% |
GILEAD LAUNCHES CLINICAL TRIAL OF CORONAVIRUS-FIGHTING REMDESIVIR INHALED VERSION
Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.
CLICK HERE TO READ MORE ON FOX BUSINESS
The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.
Gilead shares were up nearly 2% at $76.14 in trading before the bell.